Papilloma Virus Vaccine Therapy in Treating Young Patients With Recurrent Papilloma of the Larynx
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002454|
Recruitment Status : Unknown
Verified January 2002 by National Cancer Institute (NCI).
Recruitment status was: Active, not recruiting
First Posted : February 27, 2004
Last Update Posted : July 26, 2011
RATIONALE: Vaccines made from papilloma virus cells may make the body build an immune response to and kill papilloma cells.
PURPOSE: Phase II trial to study the effectiveness of papilloma virus vaccine in treating young patients with recurrent papilloma of the larynx.
|Condition or disease||Intervention/treatment||Phase|
|Precancerous Condition||Biological: autologous tumor cell vaccine||Phase 2|
OBJECTIVES: I. Determine the immune response in patients with juvenile papilloma of the larynx treated with autogenous vaccine derived from each patient's own tumor.
OUTLINE: Patients receive autogenous papilloma vaccine intradermally and subcutaneously weekly for 20 weeks.
PROJECTED ACCRUAL: Not specified
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Phase II Study of Immunotherapy With Autogenous Papilloma Vaccine in Patients With Recurrent Juvenile Papilloma of the Larynx|
|Study Start Date :||December 1971|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00002454
|United States, New Jersey|
|New Jersey Medical School|
|Newark, New Jersey, United States, 07103-2714|
|Study Chair:||James M. Oleske, MD||Rutgers, The State University of New Jersey|